Pharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male Subjects

Orion Corporation, Orion Pharma1 个研究点分布在 1 个国家目标入组 20 人开始时间: 2017年4月19日最近更新: 2017年9月26日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Orion Corporation, Orion Pharma
入组人数: 20
试验地点: 1
主要终点: Pharmacokinetics (Cmax) of levodopa

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of the study is to investigate PK of levodopa in plasma after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104 and compared to the PK of standard IR and CR levodopa formulations in the same combination.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: Male
接受健康志愿者: 是

入选标准

•Written informed consent (IC) obtained.
•Finnish speaking males between 18-65 years of age.
•Body mass index (BMI) between 19-32 kg/m2 (BMI = weight/height2).
•Weight at least 60 kg.
•Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or other intestinal problems, and no history of major gastrointestinal surgery).
•Sexually active study subjects, unless surgically sterile must adhere to a proper form of contraception (hormonal contraception or intrauterine device on female partner and an additional barrier method used at least by one of the partners) and must not donate sperm from the first study treatment administration until 3 months after the last study treatment administration.

排除标准

•Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic, endocrine, neurological or psychiatric disease or cancer (except local non-melanoma skin cancer) within the previous 2 years.
•Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. As an exception, paracetamol for occasional pain is allowed.
•Any clinically significant abnormal laboratory value or ECG (such as prolonged QTcF > 450 ms or QRS > 120 ms) that in the opinion of the investigator could interfere with the interpretation of study results or cause a health risk for the subject if he takes part in the study.
•Known hypersensitivity to the active substances or the excipients of the drugs.
•History of vasovagal collapses or vagal reactions with unexplained reason within the previous 2 years or a tendency for vasovagal reactions during blood sampling.
•HR < 40 beats per minute (bpm) or > 90 bpm in the supine position after 5 min rest at the screening visit.
•At the screening visit:systolic BP < 90 mmHg or > 150 mmHg in the supine position after 5 min rest and diastolic BP < 50 mmHg or > 90 mmHg in the supine position after 5 min rest.
•History of anaphylactic/anaphylactoid reactions.
•Strong tendency to motion sickness.
•Recent or current (suspected) drug abuse.
•Recent or current alcohol abuse; regular drinking of more than 21 units per week (1 unit = 4 cl spirits or equivalent).
•Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day and/or inability to refrain from the use of nicotine containing products during the study (from the screening visit to the end-of-study visit).
•Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability to refrain from using caffeine containing beverages 10 h before and during the study periods.
•Blood donation or loss of a significant amount of blood within 90 days before the first study treatment administration.
•Participation in an investigational drug study or administration of an investigational drug within 90 days before the first study treatment administration.
•Unsuitable veins for repeated venipuncture or cannulation.
•Predictable poor compliance or inability to communicate well with the study centre personnel.
•Inability to participate in all treatment periods.